Valuation: Antengene Corporation Limited

Market Cap 1.45B 1.71B 218M 198M 184M 166M 312M 20.34B 326M 2.22B 881M 10.99B 817M 800M 34.82B P/E 2026 *
3.99x
P/E 2027 * -16.3x
Enterprise Value 1.45B 1.71B 218M 198M 184M 166M 312M 20.34B 326M 2.22B 881M 10.99B 817M 800M 34.82B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 4.3x
Free-Float
62.78%
Yield 2026 *
-
Yield 2027 * -
1 day-1.39%
1 week-11.88%
Current month-10.93%
1 month-19.32%
3 months-36.53%
6 months-46.33%
Current year-34.43%
1 week 2.37
Extreme 2.37
2.95
1 month 2.37
Extreme 2.37
3.12
Current year 2.37
Extreme 2.37
6.28
1 year 2.37
Extreme 2.37
6.28
3 years 0.5
Extreme 0.5
8.16
5 years 0.5
Extreme 0.5
13.06
10 years 0.5
Extreme 0.5
22.5
Manager TitleAgeSince
Chief Executive Officer 60 27/08/2018
Chief Tech/Sci/R&D Officer 42 19/05/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 60 27/08/2018
Director/Board Member 51 08/11/2020
Director/Board Member 59 13/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
04/11/26 Other -3,472 0.0005% -
04/11/26 Other

Director

-251 0.0000%
10/09/26 Other

Director

200,000 0.0294%
Change 5-day change 1-year change 3-year change Capi.($)
-1.39%-11.88%-43.91%+55.31% 221M
+0.19%-2.90%+56.40%+69.15% 65.45B
-0.14%-1.96%+8.83%+89.74% 58.93B
+0.06%+0.51%+26.04%+87.89% 55.21B
-0.97%-4.83%+9.83%+113.88% 46.1B
-2.83%-8.73%+15.31%+22.34% 42.49B
+3.61%+3.86%+22.82%+46.39% 35.56B
-0.24%-11.77%+125.89%+647.44% 34.57B
+0.03%-1.80%+82.52%+57.74% 32.46B
+20.58%+19.64%-28.35%+482.03% 26.28B
Average +0.06%-3.70%+27.54%+167.19% 40B
Weighted average by Cap. +0.06%-2.70%+34.84%+149.65%

Financials

2026 *2027 *
Net sales 830M 976M 124M 113M 105M 94.91M 178M 11.62B 186M 1.27B 503M 6.28B 467M 457M 19.89B 338M 397M 50.6M 46.1M 42.67M 38.6M 72.41M 4.73B 75.79M 516M 205M 2.55B 190M 186M 8.09B
Net income 333M 392M 49.93M 45.49M 42.11M 38.09M 71.46M 4.66B 74.79M 509M 202M 2.52B 187M 183M 7.98B -84.79M -99.65M -12.7M -11.57M -10.71M -9.69M -18.18M -1.19B -19.03M -130M -51.37M -641M -47.66M -46.66M -2.03B
Net Debt - -
Projected Income Statement - Annual - Antengene Corporation Limited
Logo Antengene Corporation Limited
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
Employees
122
Date Price Change Volume
19/11/26 HK$2.485 -1.39% 392,500
18/11/26 HK$2.520 -0.40% 2,963,500
17/11/26 HK$2.530 -2.50% 654,500
16/11/26 HK$2.595 -4.24% 980,500
13/11/26 HK$2.710 -3.90% 503,500
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.114CNY
Average target price
4.150CNY
Spread / Average Target
+96.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Antengene Corporation Limited
  1. Stock Market
  2. Stocks
  3. 6996 Stock